Coordinator
Prof.dr. Jack A. Schalken
University Medical Centre Nijmegen
Department of Experimental Urology
PO Box 9101
6500 HB Nijmegen
The Netherlands
Phone +31 24 3614146
Fax +31 24 3541222
Email:
primaproject@uro.umcn.nl
Currently, five other FP6-projects dealing
with prostate cancer are funded by the EC:
P-MARK, concentrating on the identification
and development of new prognostic markers.
GIANT, aiming at the development of viral
and non-viral vectors for the targeted
treatment of prostate cancer.
CANCURE, a Marie Curie Early Stage Training
network, which focusses on translational
research in the field of prostate cancer.
PROMET, aiming at the detection and treatment
of minimal residual disease.
Polygene, a study into the genetic basis of
inherited prostate cancer in men.
The European Urology community will be informed
about the projects via the European Association
of Urology (EAU).
Welcome to PRIMA PROJECT
PROSTATE CANCER INTEGRAL MANAGEMENT APPROACH
Prostate cancer is the second most frequently diagnosed cancer
in the Western male population. For localized disease, radical
therapies aiming at eradicating all malignant processes in the
prostate gland are available that can cure the patient. However,
there is currently no effective treatment for non-localized
prostate cancer.
For more than six decades androgen ablative therapies are the
state of the art in the management of prostate cancer. Unfortunately,
this treatment should be considered palliative,
since hormone therapy unresponsive lesions will develop, the majority
of which spread to the bone, a site where metastases cause
great morbidity ultimately leading to a painful
death.
In this project a multidisciplinary effort is proposed to combat
the most lethal aspect of prostate cancer, i.e. hormone therapy
unresponsive, bone metastatic lesions.
PRIMA is an Integrated Project (IP) subsidised by
the European Commission through the 6th framework programme.
